Actively Recruiting
Study of Pirtobrutinib and Mosunetuzumab to Treat Adults With Relapsed or Refractory Grade 1 to 3a Follicular Lymphoma
Led by University of Washington · Updated on 2026-06-04
22
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how well pirtobrutinib and mosunetuzumab work together to treat patients with grade 1-3a follicular lymphoma FL that has returned after improvement or has not responded to previous treatments. Pirtobrutinib blocks a protein called Bruton tyrosine kinase BTK that helps cancer cells grow, while mosunetuzumab helps the immune systems T cells attack the lymphoma cells. This combination may kill more cancer cells and reduce some side effects related to T cell activation. Patients take pirtobrutinib by mouth once daily starting one week before mosunetuzumab treatment and continue for up to 52 weeks. Mosunetuzumab is given either under the skin or into a vein on days 1, 8, and 15 during the first treatment cycle, then on day 1 of each following 21-day cycle for up to 17 cycles unless the disease worsens or side effects become unacceptable. Those who achieve complete remission after 8 cycles stop mosunetuzumab. The study also involves collecting blood and swab samples, tissue biopsies, CT and PETCT scans, and possibly bone marrow tests. Participants are closely monitored throughout treatment and afterward with follow-up visits 30 days after treatment ends and then periodically for up to 4 years. Researchers will assess outcomes such as complete remission rate after 8 cycles, progression-free survival, overall survival, and adverse events. Various laboratory tests, imaging, and questionnaires are used to track treatment effects, safety, and disease status over time.
CONDITIONS
Brief Title
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
Research Team
M
Mengyang Di, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here